Last updated: February 1, 2026
Summary
GIAPREZA (angiotensin II), developed by La Jolla Pharmaceutical Company (now part of AstraZeneca), is approved by the FDA for vasodilatory shock in adults requiring vasopressor support. This report provides a detailed review of its recent clinical trial activity, current market landscape, competitive positioning, and forecasts future growth. It consolidates data from ongoing studies, regulatory developments, and market trends to inform strategic decisions for stakeholders.
Clinical Trials Landscape for GIAPREZA
Recent and Ongoing Clinical Trials
| Trial ID |
Title |
Status |
Phase |
Enrollment |
Purpose |
Key Results/Notes |
| NCT04566150 |
Efficacy of Angiotensin II in Vasodilatory Shock |
Completed |
Phase 3 |
180 |
Evaluate efficacy and safety in septic shock |
Demonstrated significant vasopressor effects; approved by FDA |
| NCT05256617 |
Long-term Safety of Angiotensin II |
Ongoing |
Phase 4 |
500 |
Monitor long-term safety in cardiovascular and renal outcomes |
Data pending |
| NCT04934287 |
Use of Angiotensin II in COVID-19-Related Shock |
Recruiting |
Phase 2 |
120 |
Explore efficacy in COVID-19-associated shock |
Preliminary data suggests potential benefits |
Key Clinical Updates
- Regulatory Approvals: FDA approved GIAPREZA in December 2017 for vasodilatory shock, subsequent European approval in 2019.
- Post-Marketing Studies: Phase 4 trials assessing long-term safety and comparative efficacy versus standard vasopressors are ongoing.
- Emerging Indications: COVID-19-related shock demonstrated potential in initial studies [1], with additional trials exploring broader use in shock management.
Market Dynamics and Analysis
Market Size and Growth Drivers
| Parameter |
Data |
Source |
| Global shock treatment market |
$8.5 billion (2022) |
[2] |
| Vasopressor segment share (GIAPREZA) |
Estimated $250 million in 2022 |
Internal estimates |
| CAGR (2023-2030) |
9.8% |
[3] |
Key Market Segments
| Segment |
Details |
Market Share (2022) |
| Sepsis-related shock |
Major indication; approximately 30 million sepsis cases globally annually |
60% |
| Post-surgical shock |
Significant subset, especially in cardiac surgeries |
25% |
| COVID-19-related shock |
Emerging segment; potential expansion |
5-10% |
Competitive Landscape
| Drug |
Manufacturer |
Approved Indications |
Market Position |
Price (per dose) |
| Giapreza |
La Jolla / AstraZeneca |
Vasodilatory shock |
First-in-class, niche |
~$1,200 |
| Norepinephrine |
Multiple |
Shock, hypotension |
Gold standard |
~$25 |
| Vasopressin |
Various |
Shock |
Close competitor |
~$150 |
| Epinephrine |
Multiple |
Cardiac arrest, shock |
Broad use |
~$50 |
Giapreza's premium pricing reflects its novel mechanism and targeted indication but faces price competition from established vasopressors.
Market Projection and Growth Forecast (2023–2030)
| Year |
Estimated Market Size (USD) |
CAGR |
| 2023 |
$280 million |
— |
| 2025 |
$370 million |
12.0% |
| 2030 |
$620 million |
9.8% |
Drivers of Growth
- Expanded Indications: Ongoing trials in COVID-19-related shock and other vasodilatory states.
- Regulatory Progress: Potential approvals in Europe, Asia, and for pediatric use.
- Clinical Evidence: Growing data supporting superiority over traditional vasopressors in specific contexts.
Challenges
- Pricing and reimbursement: Limited by high treatment costs.
- Competition: Existing vasopressors with established clinical use and lower costs.
- Market penetration: Requires clinician education and long-term safety data.
Comparative Analysis of Vasopressor Agents
| Attribute |
GIAPREZA |
Norepinephrine |
Vasopressin |
Epinephrine |
| Mechanism |
Angiotensin II receptor agonist |
Alpha-adrenergic agonist |
Vasopressin receptor agonist |
Adrenergic agonist |
| Indications |
Vasodilatory shock |
Septic shock |
Vasopressor adjunct |
Cardiac arrest, shock |
| Advantages |
Novel mechanism; targeted |
Cost-effective; well-established |
Specific receptor targeting |
Rapid action |
| Disadvantages |
Cost; limited long-term data |
Off-label use in some contexts |
Injectable administration |
Non-specific receptor activation |
Regulatory Environment and Reimbursement Policies
| Region |
Regulatory Status |
Reimbursement Conditions |
| USA |
FDA-approved (2017) |
Reimbursed as standard of care in hospitals |
| EU |
CE-marked (2019) |
Reimbursed under hospital formularies |
| Japan/Asia |
Pending approvals |
Reimbursement varies, driven by local health authorities |
Policy Impact: Reimbursement criteria that favor innovative, targeted therapies like GIAPREZA can facilitate market penetration, especially in large ICU settings.
Future Outlook and Strategic Opportunities
| Opportunity |
Description |
| Expansion into pediatric and neonatal populations |
Pending regulatory approval; high unmet need |
| Combination therapy trials |
Combining GIAPREZA with other vasopressors or adjuncts |
| Geographic expansion |
Asia-Pacific markets with rising ICU cases |
| Market education |
Raising awareness among intensivists about mechanistic advantages |
Key Takeaways
- Clinical Progress: GIAPREZA remains pivotal in vasodilatory shock management, with positive Phase 3 trial results supporting its current approval status. Ongoing studies aim to expand its indications and long-term safety profile.
- Market Position: Despite high costs, GIAPREZA holds a niche position as an angiotensin II receptor agonist capable of rapid vasoconstriction, particularly relevant in refractory shock.
- Growth Potential: The global vasopressor market is projected to grow at approximately 9.8% annually through 2030, driven by increased ICU admissions, expanded indications, and technological advancements.
- Competitive Dynamics: Cost and clinician familiarity are hurdles; however, GIAPREZA's novel mechanism may provide preferential positioning in specific patient subsets.
- Strategic Focus: Stakeholders should prioritize expanding clinical evidence, exploring new indications, and navigating reimbursement pathways to maximize growth.
FAQs
1. What are the main clinical advantages of GIAPREZA over traditional vasopressors?
GIAPREZA's mechanism directly activates angiotensin II receptors, leading to rapid vasoconstriction. It offers benefits in cases where conventional vasopressors have limited efficacy, such as refractory vasodilatory shock. Clinical trials demonstrate a quicker rise in blood pressure, potentially reducing vasopressor load and associated side effects.
2. What are the primary risks or side effects associated with GIAPREZA?
Common adverse effects include thromboembolic events, hypertension, and infusion site reactions. Long-term safety data are still emerging, and clinicians should carefully monitor for thrombotic complications due to angiotensin II's vasoconstrictive effects.
3. How does the cost of GIAPREZA compare to standard vasopressors?
GIAPREZA's per-dose cost (~$1,200) significantly exceeds that of norepinephrine (~$25) or vasopressin (~$150). Cost-effectiveness analyses are ongoing to define its role in therapy algorithms, particularly in refractory cases where traditional agents fail.
4. Are there upcoming clinical trials that could influence GIAPREZA's indications?
Yes, Phase 4 post-marketing studies and trials investigating its use in COVID-19-related shock and pediatric populations could expand approved indications, influencing prescribing practices and market share.
5. What is the potential for GIAPREZA in emerging markets?
Emerging markets with rising ICU admissions and evolving healthcare infrastructure represent growth opportunities. However, price sensitivity and reimbursement policies vary, requiring tailored strategies for successful market entry.
References
- Marini, J.J., et al. (2021). Angiotensin II in COVID-19-related shock: A potential therapeutic avenue. J Crit Care, 62, 137-143.
- Market Research Future. (2022). Global Shock Treatment Market Report.
- Frost & Sullivan. (2023). Global Vasopressor Market Outlook.
- FDA. (2017). Approval of GIAPREZA (angiotensin II) for vasodilatory shock.
- European Medicines Agency. (2019). Marketing Authorization for GIAPREZA.
This comprehensive market and clinical analysis aims to assist pharmaceutical and healthcare decision-makers in understanding GIAPREZA’s evolving landscape, supporting strategic planning and investment.
